Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035017) METHODS OF TREATING AUTOIMMUNE CONDITIONS IN PATIENTS WITH GENETIC VARIATIONS IN DCR3 OR IN A DCR3 NETWORK GENE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2017/035017 International Application No.: PCT/US2016/047872
Publication Date: 02.03.2017 International Filing Date: 19.08.2016
IPC:
A61K 39/395 (2006.01) ,A61K 49/00 (2006.01) ,C07K 16/00 (2006.01) ,C07K 16/28 (2006.01)
[IPC code unknown for A61K 39/395][IPC code unknown for A61K 49][IPC code unknown for C07K 16][IPC code unknown for C07K 16/28]
Applicants:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA [US/US]; 34th Street And Civic Center Boulevard Philadelphia, PA 19104, US
Inventors:
HAKONARSON, Hakon; US
KAO, Charlly; US
CARDINALE, Christopher; US
PANDEY, Rahul; US
LI, Yun, Rose; US
Agent:
RIGAUT, Kathleen, D.; US
HAGAN, Patrick, J.; US
HERRELL, Roger, W.; US
PACE, Vincent, T.; US
RIGAUT, Kathleen, D.; US
Priority Data:
62/208,38321.08.2015US
62/320,40008.04.2016US
Title (EN) METHODS OF TREATING AUTOIMMUNE CONDITIONS IN PATIENTS WITH GENETIC VARIATIONS IN DCR3 OR IN A DCR3 NETWORK GENE
(FR) PROCÉDÉS DE TRAITEMENT DE CONDITIONS AUTO-IMMUNES CHEZ DES PATIENTS COMPRENANT DES VARIATIONS GÉNÉTIQUES DANS DCR3 OU DANS UN GÈNE DE RÉSEAU DE DCR3
Abstract:
(EN) The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TLl A, and FasL, such as anti -LIGHT, anti-TLl A, and anti -FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.
(FR) La présente invention concerne des procédés de traitement de conditions auto-immunes chez des patients atteints d'altérations génétiques dans le gène TNFRSF6B, lequel code pour la protéine du récepteur leurre 3 (DcR3), par exemple des procédés qui réduisent l'expression, la sécrétion, ou l'activité de liaison de ligand de DcR3. Par exemple, dans certains modes de réalisation, ces conditions peuvent être traitées avec des molécules qui inhibent l'activité de ligands de DcR3, tels que LIGHT, TLI A, et FasL, tel que des anticorps anti-LIGHT, anti-TLI A et anti-FasL, ou des inhibiteurs du mécanisme d'action NF-κB non canonique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)